Evidence map›Paper›PMID 35407443›Full record

ArticleJournal of clinical medicine2022

ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.

Hiroaki Takaya, Tadashi Namisaki, Shohei Asada, Satoshi Iwai, Takahiro Kubo, Junya Suzuki, Masahide Enomoto, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Allele-selective von Willebrand factor silencing.Research and practice in thrombosis and haemostasis · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Recombinant ADAMTS-13 Improves Survival of Mice Subjected to Endotoxemia.International journal of molecular sciences · 2023
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Hiroaki TakayaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Tadashi NamisakiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0002-3158-5318
Shohei AsadaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Satoshi IwaiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0003-3575-5609
Takahiro KuboDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Junya SuzukiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Masahide EnomotoDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Yuki TsujiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Yukihisa FujinagaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0003-2402-574X
Norihisa NishimuraDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0002-6295-3283
Yasuhiko SawadaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Kosuke KajiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Hideto KawarataniDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0002-4361-0592
Kei MoriyaDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Takemi AkahaneDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.ORCID 0000-0002-6675-0475
Masanori MatsumotoDepartment of Blood Transfusion Medicine, Nara Medical University, Kashihara 634-8522, Japan.
Hitoshi YoshijiDepartment of Gastroenterology, Nara Medical University, Kashihara 634-8522, Japan.
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ADAMTS13 specifically cleaves the multimeric von Willebrand factor (VWF), and an imbalance between ADAMTS13 activity (ADAMTS13:AC) and VWF antigen (VWF:Ag) levels is associated with the severity of liver cirrhosis (LC). However, the reason for this imbalance in patients with LC is unknown. This study investigated the relationship among ADAMTS13:AC, VWF:Ag, and endotoxin (Et) levels in patients with LC. ADAMTS13:AC and VWF:Ag levels were determined using ELISA, whereas Et levels were estimated using a chromogenic substrate assay. The levels of ADAMTS13 inhibitor (ADAMTS13:INH) were evaluated by measuring the extent that heat-inactivated patient's plasma reduces the ADAMTS13:AC of the control. The status (degraded, normal, or unusually large [UL]) of the VWF multimer (VWFM) was determined through vertical agarose gel electrophoresis. ADAMTS13:AC, VWF:Ag, and Et levels decreased, increased, and increased, respectively, with the severity of LC. Patients with cirrhosis with high Et levels had lower and higher ADAMTS13:AC and VWF:Ag levels, respectively, than those with low Et levels. Patients with cirrhosis with detectable ADAMTS13:INH had higher Et levels than those with undetectable ADAMTS13:INH. Patients whose VWFM was either normal or UL had higher Et levels than those with degraded VWFM. In conclusion, ADAMTS13, VWF, and Et may be interrelated and associated with the severity of LC via hypercoagulability.

Indexed as

ADAMTS13endotoxinhypercoagulabilityliver cirrhosisvon Willebrand factor

Identifiers

PMID35407443
PMCPMC8999602
OpenAlexW4220680851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.